Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 3/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530556 | 0.90 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2529708 | 0.89 | RXRA (0.65) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL4327039 | 0.89 | RXRA (0.65) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL4325346 | 0.89 | HDAC1 (0.63) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2529193 | 0.88 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2529963 | 0.88 | HDAC1 (0.58) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL4328651 | 0.82 | NR4A2 (0.74) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2531133 | 0.82 | NR4A2 (0.74) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2529192 | 0.81 | NR4A2 (0.67) | HDAC1HDAC2HDAC8HDAC3HDAC6 | |
| SCHEMBL2526544 | 0.81 | RXRA (0.60) | HDAC1HDAC2HDAC8HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | claimed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | claimed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | claimed |
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | HDAC1, HDAC5, HDAC7 | HDAC1 1/4885HDAC2 5/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.